115 related articles for article (PubMed ID: 11405658)
1. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
Bartolomé-Nebreda JM; Patiño-Molina R; Martín-Martínez M; Gómez-Monterrey I; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
J Med Chem; 2001 Jun; 44(13):2219-28. PubMed ID: 11405658
[TBL] [Abstract][Full Text] [Related]
2. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Cenarruzabeitia E; Latorre M; Del Río J; Herranz R
J Med Chem; 2001 Nov; 44(24):4196-206. PubMed ID: 11708921
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
[TBL] [Abstract][Full Text] [Related]
4. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
[TBL] [Abstract][Full Text] [Related]
5. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
Bartolomé-Nebreda JM; Gómez-Monterrey I; García-López MT; González-Muñiz R; Martín-Martínez M; Ballaz S; Cenarruzabeitia E; LaTorre M; Del Río J; Herranz R
J Med Chem; 1999 Nov; 42(22):4659-68. PubMed ID: 10579828
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
Boden PR; Higginbottom M; Hill DR; Horwell DC; Hughes J; Rees DC; Roberts E; Singh L; Suman-Chauhan N; Woodruff GN
J Med Chem; 1993 Mar; 36(5):552-65. PubMed ID: 7684452
[TBL] [Abstract][Full Text] [Related]
7. beta-Turned dipeptoids as potent and selective CCK(1) receptor antagonists.
Martín-Martínez M; De La Figuera N; Latorre M; Herranz R; García-López MT; Cenarruzabeitia E; Del Río J; González-Muñiz R
J Med Chem; 2000 Oct; 43(20):3770-7. PubMed ID: 11020292
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
[TBL] [Abstract][Full Text] [Related]
9. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
[TBL] [Abstract][Full Text] [Related]
10. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
Low CM; Black JW; Broughton HB; Buck IM; Davies JM; Dunstone DJ; Hull RA; Kalindjian SB; McDonald IM; Pether MJ; Shankley NP; Steel KI
J Med Chem; 2000 Sep; 43(19):3505-17. PubMed ID: 11000005
[TBL] [Abstract][Full Text] [Related]
11. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
13. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
Müller CE; Geis U; Grahner B; Lanzner W; Eger K
J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
[TBL] [Abstract][Full Text] [Related]
14. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Tabuchi S; Nakanishi I; Satoh Y
Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
[TBL] [Abstract][Full Text] [Related]
15. Structure activity of C-terminal modified analogs of Ac-CCK-7.
Tilley JW; Danho W; Shiuey SJ; Kulesha I; Sarabu R; Swistok J; Makofske R; Olson GL; Chiang E; Rusiecki VK
Int J Pept Protein Res; 1992 Apr; 39(4):322-36. PubMed ID: 1385345
[TBL] [Abstract][Full Text] [Related]
16. CCK(2) receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic.
Gibson SE; Guillo N; Jones JO; Buck IM; Kalindjian SB; Roberts S; Tozer MJ
Eur J Med Chem; 2002 May; 37(5):379-89. PubMed ID: 12008052
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
19. Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.
Shiosaki K; Lin CW; Kopecka H; Craig RA; Bianchi BR; Miller TR; Witte DG; Stashko M; Nadzan AM
J Med Chem; 1992 May; 35(11):2007-14. PubMed ID: 1375964
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
